Abstract Number: PB2315
Meeting: ISTH 2020 Congress
Theme: Venous Thromboembolism and Cardioembolism » VTE Epidemiology
Background: Allogeneic hematopoietic stem cell transplantation (aHSCT) involves multiple complex risk factors that can place the patient under an increased risk of venous thromboembolism (VTE). Limited studies in aHSCT recipients have reported a wide range in the incidence of VTE, from 0.5% to 13%.
Aims: To study the incidence of VTE following aHSCT and to study the prevalence of risk factors commonly associated with VTE in this setting.
Methods: We studied a retrospective cohort of adult patients ≥18 years of age who underwent aHSCT between January 1, 2016, and December 31, 2019, at the Mazumdar Shaw Medical Center, Bangalore. Patient, transplant, and outcome-related factors were extracted from the transplantation database. A pharmacy and radiology record review was done to identify patients with VTE who received systemic anticoagulation.
Results: A cohort of 158 patients who underwent aHSCT in the time period mentioned were studied. The Baseline characteristics of the cohort are as shown in Table 1. The incidence of VTE was 2.5% with a median follow-up period of 5 months (Range 1 – 42 months). Two patients had upper limb deep vein thrombosis (DVT), 1 patient had thrombosis of medullary veins of the brain and, 1 patient had splanchnic vein thrombosis with a median time to development of VTE of 36 days, 18 days, and, 20 days respectively. Prevalence of risk factors such as central line, prolonged hospitalizations, myeloablative conditioning, acute or chronic graft versus host disease (GVHD), prior VTE, and family history of VTE was studied (Table 2.). The patients had a median of 3 risk factors in both the group of patients (VTE versus no VTE).
Conclusions: VTE is a rare complication following aHSCT (2.5% incidence in this study and the patients had a median of 3 risk factors) and further studies are warranted in this special population subset.
| Baseline characterstics | N (Total =158) |
| Median age (range) | 34.5 years (18,69) |
| Males: females | 101: 57 |
| Diagnosis: | |
| Acute leukemias, myelodysplastic syndromes & other malignancies | 135 |
| Aplastic anemia, hemoglobinopathies & others | 23 |
| Donor type: | |
| Matched sibling: matched unrelated: haplo-identical | 112: 9: 37 |
| Disease status: | |
| First remission: second remission | 98: 37 |
[Table 1. Baseline characteristics of patients]
| Risk factors | N (Total=158) |
| Central venous catheter (tunelled or non-tunelled) & PICC | 158 |
| Family history of VTE | 0 |
| Previous history of VTE | 4 |
| Prolonged hospitalizations (>30 days) | 9 |
| Myeloablative conditioning | 73 |
| Acute GVHD: Chronic GVHD | 49: 19 |
[Table 2. Prevalence of risk factors for VTE]
To cite this abstract in AMA style:
Ram S B, Nataraj KS, Prabhu S, Dalal H, Polisetty A, Kumar S, Shah A, Karthick RG, Harimadhavan M, Damodar S. A Retrospective Study of Incidence of Venous Thromboembolism (VTE) and Prevalence of Risk Factors Associated with VTE in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/a-retrospective-study-of-incidence-of-venous-thromboembolism-vte-and-prevalence-of-risk-factors-associated-with-vte-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-a-singl/. Accessed January 23, 2022.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/a-retrospective-study-of-incidence-of-venous-thromboembolism-vte-and-prevalence-of-risk-factors-associated-with-vte-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-a-singl/